Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer

NCT06038578 is registered in ClinicalTrials.gov with Toray Industries, Inc as lead sponsor.

NCT NCT06038578
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06038578 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer
Lead sponsor
Toray Industries, Inc
Phase
Phase 2
Overall status
Recruiting
Start date
October 4, 2023
Completion date
October 31, 2027
Enrollment
146 (estimated)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

gastric adenocarcinoma, gastric cancer, gastroesophageal junction adenocarcinoma